Large Pharmaceuticals
Market Cap
₹1,12,149 ₹1.12 L Cr.
P/E
24.85
PEG
2.54
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The bull thesis activates if Saroglitazar gains US approval ahead of schedule with broad label potential, causing specialty revenue to rapidly re-rate the multiple from generic to innovation-led pharma.

The bear case crystallizes if the Saroglitazar NDA is rejected or delayed, removing the critical high-margin recovery driver and compressing margins through FY29 as US generics erosion accelerates.

The base case depends on International Markets compounding at 25% for five years to offset North America's declining share, with any deceleration posing the single largest risk to the revenue trajectory.

Get your Reports on Demand
Get detailed, analyst-grade reports with actionable insights to make informed investment decisions.
  Flat 20% OFF
 for Tijori Premium Users
  Flat 20% OFF  for Tijori Premium Users
5Y Revenue & EBITDA Estimates
KEY TRIGGERS TO WATCH
  • The bull thesis activates if Saroglitazar gains US approval ahead of schedule with broad label potential, causing specialty revenue to rapidly re-rate the multiple from generic to innovation-led pharma.
  • The bear case crystallizes if the Saroglitazar NDA is rejected or delayed, removing the critical high-margin recovery driver and compressing margins through FY29 as US generics erosion accelerates.
  • The base case depends on International Markets compounding at 25% for five years to offset North America's declining share, with any deceleration posing the single largest risk to the revenue trajectory.
Bear : -0.8% CAGR • ₹8,140 Cr
Base: 10.8% CAGR • ₹14,140 Cr
Bull: 15.5% CAGR • ₹17,400 Cr
Buy Report $5
Management Credibility Report
TRACK RECORD
  • Management is highly credible on financial guidance, consistently under-promising and over-delivering on revenue growth and EBITDA margins by wide margins, making their statements reliable floors rather than targets.
  • Conversely, management's pipeline timeline commitments, especially for Saroglitazar clinical milestones, have systematically slipped by 12-18 months, requiring a credibility discount on all future R&D milestone projections.
  • The underlying pattern is a conservative financial culture coupled with structural optimism in drug development timelines, which inflates expectations without malicious intent but warrants investor adjustment.
Met : 16
Progress: 1
Missed : 3
Buy Report $5
WORST-CASE SCENARIO
  • The overall risk profile is fundamentally healthy with clean audits, strong solvency, and no share dilution, but margins are heavily dependent on foreign exchange gains that mask an underlying contraction.
  • The most severe existential threat is a potential USFDA import alert escalation at the Baddi facility, which could disrupt 40% of US revenue.
  • Cash flow generation has deteriorated sharply (H1 FY26 OCF down 74% YoY), and persistent weakness could constrain strategic flexibility despite a strong liquid asset buffer.
High Risk : 0
Medium Risk : 3
Low Risk : 14
Buy Report $5
Powered By
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material